Navigation Links
Anadys Pharmaceuticals Reports First Quarter 2011 Financial Results and Highlights
Date:5/5/2011

SAN DIEGO, May 5, 2011 /PRNewswire/ -- Anadys Pharmaceuticals, Inc. (Nasdaq: ANDS), a biopharmaceutical company dedicated to improving patient care by developing novel medicines for the treatment of hepatitis C, today reported its program highlights and financial results for the first quarter ended March 31, 2011.

"The ANA598 Phase IIb study currently underway will expand the profile of ANA598 in important ways," said Steve Worland, Ph.D., President and CEO of Anadys.  "We expect to increase the ANA598 safety database by approximately 200 patients, with dosing through 24 weeks completed by year-end, and to characterize ANA598's activity in combination with pegylated interferon and ribavirin in treatment-experienced patients.  The acquisition of these data should significantly enhance ANA598's readiness for Phase III activities."

Development Program Highlights

  • ANA598 Phase IIb Study.  During the first quarter, Anadys commenced dosing HCV patients in an ongoing Phase IIb study in which ANA598 is being tested in combination with interferon and ribavirin in both treatment-naive patients and patients who failed a prior course of therapy with interferon and ribavirin.  Approximately 275 patients are expected to be enrolled in the study.  The primary endpoint of the study is Sustained Virological Response 24 weeks after patients complete treatment, known as SVR24.  The Company expects to receive antiviral response data through 12 weeks for all patients, including the 8 week timepoint used for response-guided therapy in treatment-naive patients, in the third quarter of 2011.  Antiviral response data through 24 weeks are expected in the fourth quarter of 2011.  
  • ANA773 Phase IIa Study.  The Company is preparing to commence during the second quarter a 28-day study of ANA773 in combination with riba
    '/>"/>

    • SOURCE Anadys Pharmaceuticals, Inc.
    Copyright©2010 PR Newswire.
    All rights reserved

    0

    GOOD

    Page: 1 2 3 4 5

    Related medicine technology :

    1. Anadys Pharmaceuticals Presents Preclinical Results on ANA598, a Non-Nucleoside Inhibitor of the NS5B Polymerase, at the 14th International Symposium on Hepatitis C Virus and Related Viruses
    2. Anadys Pharmaceuticals Announces Positive Results for ANA598 in Animal Model of Chronic Hepatitis C Virus Infection
    3. Anadys Pharmaceuticals Presents Data on ANA598, a Non-Nucleoside Inhibitor of the HCV Polymerase, at the 21st International Conference on Antiviral Research
    4. Anadys Pharmaceuticals Initiates Phase I Clinical Trial of ANA598
    5. Anadys Pharmaceuticals Resumes Clinical Investigation of TLR7 Mechanism in HCV
    6. Anadys Pharmaceuticals Announces Successful Outcome of ANA598 Healthy Volunteer Study and Finalization of Study Design for Phase Ib Trial in HCV Patients
    7. Anadys Pharmaceuticals to Present at the JMP Securities Healthcare Focus Conference
    8. Anadys Pharmaceuticals Announces Single Dose Safety and Pharmacokinetics Results for ANA598 in Healthy Volunteers
    9. Anadys Pharmaceuticals Commences Dosing in Phase II Study of ANA598
    10. Anadys Pharmaceuticals to Present at Two Upcoming Investor Conferences
    11. Anadys Pharmaceuticals to Present at the Oppenheimer Healthcare Conference
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:5/20/2013)... Calif. , May 20, 2013 Sequent ... mark for the SL ("Single Layer") family of WEB ... controlled release of these new models in select neurovascular ... profile and superior navigability that will enable physicians to ... platform. The SL configurations are made possible ...
    (Date:5/20/2013)... ATLANTA , May 20, 2013  Atlantic ... developed and is commercializing a unique technology to ... founder and President, Anthony Soscia ... the Atlanta Business Chronicle ,s Health-Care Heroes ... Atlanta Business Chronicle to honor individuals and ...
    (Date:5/20/2013)... , May 20, 2013 Enrollment of ... Therapeutics, Phase 2b dose-finding clinical trial of product candidate ... the foundational treatment for Type 2 diabetes. Elcelyx expects ... U.S. program in June. Results of the trial,s primary ... in late summer, and the read-out for long-term glucose ...
    Breaking Medicine Technology:Sequent Medical, Inc. Launches New SL Family of WEB Aneurysm Embolization Devices 2Atlantic Pharmaceuticals President Named Health Care Hero Finalist in Atlanta Business Chronicle for Drug Abuse Deterrent Technology 2Elcelyx Therapeutics Enrolling Phase 2b Trial of NewMet for Type 2 Diabetes 2Elcelyx Therapeutics Enrolling Phase 2b Trial of NewMet for Type 2 Diabetes 3Elcelyx Therapeutics Enrolling Phase 2b Trial of NewMet for Type 2 Diabetes 4
    ... MONMOUTH JUNCTION, N.J., Sept. 11 Signum Biosciences, Inc has ... Phase II grant by the National Institute of Allergy and ... STM (Signal Transduction Modulator) anti-inflammatory technology for the treatment of ... 2008, NIH/NIAID awarded Signum a SBIR Phase I grant to ...
    ... , , ROCHESTER, Minn., Sept. 11 ... mice were associated with good central nervous system repair in multiple ... effective therapies for patients with MS and for predicting MS patients, ... European Committee for Treatment and Research in Multiple Sclerosis in Dusseldorf, ...
    Cached Medicine Technology:Signum Biosciences Awarded Phase II SBIR Grant by the NIH for the Treatment of Rosacea 2Researchers Identify Two Genes as Potential Therapeutic Targets for Multiple Sclerosis 2Researchers Identify Two Genes as Potential Therapeutic Targets for Multiple Sclerosis 3
    (Date:5/21/2013)... The National Resident Matching Program NRMP® ... its Board of Directors. Hal B. Jenson, M.D., ... of Medicine, has been named President. Maria C. ... of California San Diego, is the President-Designate, and Glenn ... Medical Center, is the Secretary-Treasurer. Kenneth B. Simons, ...
    (Date:5/21/2013)... Dr. James C. Wittig, Chief of ... Sarcoma Division of the John Theurer Cancer Center at ... named one of the top 13 Orthopedic Oncologists in ... Wittig is one of approximately 125 surgeons in America ... by surveying thought leaders in the field of Oncology. ...
    (Date:5/21/2013)... 21, 2013 Brunswick Laboratories, Inc. ... the development and standardization of validated analytical methods, ... Brunswick Laboratories and the USDA, as a First ... This decision comes after extensive review by an ... Harnly of the U.S. Department of Agriculture. , ...
    (Date:5/21/2013)... According to the Center for Disease Control and ... year. Over 800,000 of these bites require medical attention, ... should be aware of the danger that dog bites pose ... and children may sustain more serious injuries than an adult. ... the ages of 5 and 9 are at the greatest ...
    (Date:5/20/2013)... USA Book News announced Monday that "The ... won the top honor in its 2013 International Book ... multitude of international titles published from 2011-2013, "The Infinity ... both mainstream and new age audiences looking to improve ... , “The Infinity Zone” is a phenomenon ...
    Breaking Medicine News(10 mins):Health News:New Board of Directors Leadership for The Match- National Resident Matching Program® 2Health News:New Board of Directors Leadership for The Match- National Resident Matching Program® 3Health News:James C. Wittig, MD, Selected as one of America's Top 13 Orthopaedic Oncologists 2Health News:James C. Wittig, MD, Selected as one of America's Top 13 Orthopaedic Oncologists 3Health News:AOAC International Approves ORAC as First Action Official Method 2Health News:Personal Injury Law Firm Announces New Informational Graphic Regarding Dog Bite Injuries 2Health News:Mystic Ink Publishing's "The Infinity Zone" Wins Top Honor - International Book Awards 2Health News:Mystic Ink Publishing's "The Infinity Zone" Wins Top Honor - International Book Awards 3
    ... 19 PAREXEL International Corporation (Nasdaq: PRXL ) ... Monday, January 26, 2009 after the close of the stock ... at www.parexel.com and on the PR Newswire website ... live webcast at 10:00 a.m. ET on Tuesday, January 27, ...
    ... a free prostate cancer screening and educational information on Monday 1/19 ... providing Atlanta residents with information about prostate health, the Prostate Proactivity ... (RCOG) and NewsTalk 750 WSB. , ... Atlanta, GA ...
    ... A collection of hospitals in eight cities around the ... surgical checklist during major operations can lower the incidence of ... study was led by researchers from the Harvard School of ... and the results are published Online First on Wednesday, January ...
    ... Believe in Khanna LASIK and change (improve) vision especially if you ... ... 18, 2009 -- In honor of the Presidential Inauguration on Tuesday, ... free LASIK surgery to any US citizen named "Barack Hussein Obama". ...
    ... Takes only minutes when temperatures drop to cause permanent damage, ... -- When the weather outside is frigid, do you know ... minutes for exposed skin to become frostbitten if the temperature ... at 20 miles per hour or more," Dr. Taizoon Baxamusa, ...
    ... the HIMSS Analytics Database, 85 percent of hospitals in the contracting phase ... since November 2007, when CCHIT released its first acute care or inpatient ... ... data from the HIMSS Analytics Database, 85 percent of hospitals in the ...
    Cached Medicine News:Health News:PAREXEL Announces Date of Second Quarter Fiscal Year 2009 Earnings Release and Conference Call 2Health News:Radiotherapy Clinics of Georgia and NewsTalk 750 WSB Team Up to Promote Prostate Proactivity 2Health News:Radiotherapy Clinics of Georgia and NewsTalk 750 WSB Team Up to Promote Prostate Proactivity 3Health News:Hospitals demonstrate surgical safety checklist drops deaths and complications by more than a third 2Health News:Hospitals demonstrate surgical safety checklist drops deaths and complications by more than a third 3Health News:Hospitals demonstrate surgical safety checklist drops deaths and complications by more than a third 4Health News:LASIK Surgery for "Barack Hussein Obama" 2Health News:Hard, Cold Facts About Frostbite 2Health News:85 Percent of Hospitals Select CCHIT Certified Products 2Health News:85 Percent of Hospitals Select CCHIT Certified Products 3Health News:85 Percent of Hospitals Select CCHIT Certified Products 4Health News:85 Percent of Hospitals Select CCHIT Certified Products 5
    SofLens Multi-Focal with unique Natra-Sight Optics designed to provide broad transition for near, intermediate and far vision, SofLens Multi-Focal lenses offer crisp, clear vision at all distances....
    An easy-to-fit high water content spherical soft lens manufactured using cast molding technology, and designed for use in the correction of myopia on a daily wear or extended wear basis....
    Bausch & Lomb SofLens59 contact lenses combine excellent performance, comfort and visual acuity providing daily wear for two week replacement....
    ... uses reflection mirrors to measure the ... after tumor removal or thyroid decompression. ... Naugle is easy to handle- with ... and plastic mounts that are placed ...
    Medicine Products: